Exercise or conversion by Walter Klemp of 14717 shares of Moleculin Biotech subject to Rule 16b-3
| MBRX Stock | USD 1.78 0.01 0.56% |
Slightly above 61% of Moleculin Biotech's investor base is looking to short. The analysis of the overall investor sentiment regarding Moleculin Biotech suggests that many traders are alarmed. Moleculin Biotech's investing sentiment can be driven by a variety of factors including economic data, Moleculin Biotech's earnings reports, geopolitical events, and overall market trends.
Moleculin |
Filed transaction by Moleculin Biotech Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
Read at macroaxis.com
Moleculin Biotech Fundamental Analysis
We analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Moleculin Biotech is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Moleculin Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Moleculin Biotech stock to make a market-neutral strategy. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics with similar companies.
Peers
Moleculin Biotech Related Equities
| ALLR | Allarity Therapeutics | 5.94 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.61 | ||||
| PMVP | Pmv Pharmaceuticals | 1.95 | ||||
| CAPR | Capricor Therapeutics | 2.53 | ||||
| IKT | Inhibikase Therapeutics | 3.43 | ||||
| ANTX | AN2 Therapeutics | 3.70 | ||||
| PULM | Pulmatrix | 4.31 | ||||
| NXTC | NextCure | 4.49 | ||||
| ATXI | Avenue Therapeutics | 4.62 | ||||
| BPTH | Bio Path | 8.41 | ||||
| CYCC | Cyclacel Pharmaceuticals | 8.89 | ||||
| AKTX | Akari Therapeutics | 9.22 | ||||
| VRAX | Virax Biolabs | 15.52 |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.